The antioxidative effect of electro-acupuncture in a mouse model of Parkinson's disease

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Wang, Haomin ^a   Pan, Yanli ^b   Xue, Bing ^c   Wang, Xinhong ^a   Zhao, Feng ^c   Jia, Jun ^c   Liang, Xibin ^d   Wang, Xiaomin ^a,c  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; MALONALDEHYDE; SUPEROXIDE DISMUTASE; ANTIOXIDANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ELECTROACUPUNCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN EXPRESSION; ULTRAVIOLET RADIATION; ACUPUNCTURE; ANIMAL; APOPTOSIS; C57BL MOUSE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; ENZYME IMMUNOASSAY; INTOXICATION; METABOLISM; NERVE CELL; SUBSTANTIA NIGRA;

MUS;

1-METHYL-4-PHENYLPYRIDINIUM; ACUPUNCTURE THERAPY; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GLUTATHIONE; HYDROGEN PEROXIDE; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE;

EID: 79956367899     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019790     Document Type: Article

References (53)

1. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, et al. (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389.
2. Floor E, Wetzel MG, (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70: 268-275.
3. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, et al. (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69: 1326-1329.
4. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, et al. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93: 2696-2701.
5. Shigenaga MK, Ames BN, (1991) Assays for 8-hydroxy-2′-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med 10: 211-216.
6. Greenamyre JT, Hastings TG, (2004) Biomedicine. Parkinson's-divergent causes, convergent mechanisms. Science 304: 1120-1122.
7. Beal MF, (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2: 325-334.
8. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, et al. (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16: 135-142.
9. Przedborski S, Vila M, (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991: 189-198.
10. Zhang J, Graham DG, Montine TJ, Ho YS, (2000) Enhanced N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in mice deficient in CuZn-superoxide dismutase or glutathione peroxidase. J Neuropathol Exp Neurol 59: 53-61.
11. Liang LP, Huang J, Fulton R, Day BJ, Patel M, (2007) An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J Neurosci 27: 4326-4333.
12. Luo D, Zhang Q, Wang H, Cui Y, Sun Z, et al. (2009) Fucoidan protects against dopaminergic neuron death in vivo and in vitro. Eur J Pharmacol 617: 33-40.
13. Moussaoui S, Obinu MC, Daniel N, Reibaud M, Blanchard V, et al. (2000) The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 166: 235-245.
14. Ren XM, (2008) Fifty cases of Parkinson's disease treated by acupuncture combined with madopar. J Tradit Chin Med 28: 255-257.
15. Zhuang X, Wang L, (2000) Acupuncture treatment of Parkinson's disease-a report of 29 cases. J Tradit Chin Med 20: 265-267.
16. Chen L, (1998) Clinical observations on forty cases of paralysis agitans treated by acupuncture. J Tradit Chin Med 18: 23-26.
17. Dos SJG Jr, Kawano F, Nishida MM, Yamamura Y, Mello LE, et al. (2008) Antidepressive-like effects of electroacupuncture in rats. Physiol Behav 93: 155-159.
18. Lee SH, Chung SH, Lee JS, Kim SS, Shin HD, et al. (2002) Effects of acupuncture on the 5-hydroxytryptamine synthesis and tryptophan hydroxylase expression in the dorsal raphe of exercised rats. Neurosci Lett 332: 17-20.
19. Rho SW, Choi GS, Ko EJ, Kim SK, Lee YS, et al. (2008) Molecular changes in remote tissues induced by electro-acupuncture stimulation at acupoint ST36. Mol Cells 25: 178-183.
20. Kung YY, Chen FP, Hwang SJ, (2006) The different immunomodulation of indirect moxibustion on normal subjects and patients with systemic lupus erythematosus. Am J Chin Med 34: 47-56.
21. Huang C, Wang Y, Chang JK, Han JS, (2000) Endomorphin and mu-opioid receptors in mouse brain mediate the analgesic effect induced by 2 Hz but not 100 Hz electroacupuncture stimulation. Neurosci Lett 294: 159-162.
22. Liang XB, Liu XY, Li FQ, Luo Y, Lu J, et al. (2002) Long-term high-frequency electro-acupuncture stimulation prevents neuronal degeneration and up-regulates BDNF mRNA in the substantia nigra and ventral tegmental area following medial forebrain bundle axotomy. Brain Res Mol Brain Res 108: 51-59.
23. Zhao LC, Shi LG, (2009) Metabolism of hydrogen peroxide in univoltine and polyvoltine strains of silkworm (Bombyx mori). Comp Biochem Physiol B 152: 339-345.
24. Placer ZA, Cushman LL, Johnson BC, (1966) Estimation of product of lipid peroxidation (malonyl dialdehyde) in biochemical systems. Anal Biochem 16: 359-364.
25. Winterbourn CC, Hawkins RE, Brian M, Carrell RW, (1975) The estimation of red cell superoxide dismutase activity. J Lab Clin Med 85: 337-341.
26. Hafemen DG, (1974) Effect of dietary selenium on erythrocyte and liver glutathione peroxidase in the rats. J Nutr 104: 580-587.
27. Anderson ME, (1985) Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol 113: 548-555.
28. Kish SJ, Morito C, Hornykiewicz O, (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 58: 343-346.
29. Saggu H, Cooksey J, Dexter D, Wells FR, Lees A, et al. (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 53: 692-697.
30. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, et al. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36: 348-355.
31. Przedborski S, Kostic V, Jackson-Lewis V, Naini AB, Simonetti S, et al. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 12: 1658-1667.
32. Klivenyi P, St Clair D, Wermer M, Yen HC, Oberley T, et al. (1998) Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiol Dis 5: 253-258.
33. Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, et al. (2001) Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Exp Neurol 167: 189-195.
34. Rabinovic AD, Hastings TG, (1998) Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 71: 2071-2078.
35. Jha N, Jurma O, Lalli G, Liu Y, Pettus EH, et al. (2000) Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 275: 26096-26101.
36. Yu YP, Ju WP, Li ZG, Wang DZ, Wang YC, et al. (2010) Acupuncture inhibits oxidative stress and rotational behavior in 6-hydroxydopamine lesioned rat. Brain Res 1336: 58-65.
37. Betarbet R, Sherer TB, Greenamyre JT, (2002) Animal models of Parkinson's disease. Bioessays 24: 308-318.
38. Dauer W, Przedborski S, (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
39. Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, et al. (2003) Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl pp. 89-100.
40. Schmidt N, Ferger B, (2001) Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 108: 1263-1282.
41. Orth M, Tabrizi SJ, (2003) Models of Parkinson's disease. Mov Disord 18: 729-737.
42. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, et al. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Proc Natl Acad Sci U S A 95: 7659-7663.
43. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, et al. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96: 5774-5779.
44. Herkenham M, Little MD, Bankiewicz K, Yang SC, Markey SP, et al. (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40: 133-158.
45. Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, et al. (1986) MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area. Neuropharmacology 25: 939-941.
46. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM, (1996) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16: 436-447.
47. Kim ST, Moon W, Chae Y, Kim YJ, Lee H, et al. (2010) The effect of electroaucpuncture for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced proteomic changes in the mouse striatum. J Physiol Sci 60: 27-34.
48. Jia J, Sun Z, Li B, Pan Y, Wang H, et al. (2009) Electro-acupuncture stimulation improves motor disorders in Parkinsonian rats. Behav Brain Res 205: 214-218.
49. Jia J, Li B, Sun ZL, Yu F, Wang X, et al. (2010) Electro-acupuncture stimulation acts on the basal ganglia output pathway to ameliorate motor impairment in Parkinsonian model rats. Behav Neurosci 124: 305-310.
50. Liang XB, Luo Y, Liu XY, Lu J, Li FQ, et al. (2003) Electro-acupuncture improves behavior and upregulates GDNF mRNA in MFB transected rats. Neuroreport 14: 1177-1181.
51. Drechsel DA, Patel M, (2008) Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 44: 1873-1886.
52. Liu XY, Zhou HF, Pan YL, Liang XB, Niu DB, et al. (2004) Electro-acupuncture stimulation protects dopaminergic neurons from inflammation-mediated damage in medial forebrain bundle-transected rats. Exp Neurol 189: 189-196.
53. Shulman LM, Wen X, Weiner WJ, Bateman D, Minagar A, et al. (2002) Acupuncture therapy for the symptoms of Parkinson's disease. Mov Disord 17: 799-802.